<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857675</url>
  </required_header>
  <id_info>
    <org_study_id>ADF30001</org_study_id>
    <nct_id>NCT00857675</nct_id>
  </id_info>
  <brief_title>A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B</brief_title>
  <official_title>A Multi-Centre, Double-Blind , Randomized, Placebo-Controlled Phase II/III Study of Adefovir Dipivoxil for the Treatment of Chinese Patients With HBeAg Positive Chronic Hepatitis B Followed by Long-Term (5 Years Total) Adefovir Dipivoxil Treatment. (Report on Year 1 and Year 2 Data)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Adefovir Dipivoxil is effective and safe in
      treatment of Chinese Patients with HBeAg positive Chronic Hepatitis B for 5 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The log10 reduction in HBV DNA from baseline at week 12 between ADV 10mg and matching placebo</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with ALT normalisation</measure>
    <time_frame>Week 52, 104, 156, 208, 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>log10 reduction in serum HBV DNA</measure>
    <time_frame>Week 52, 104, 156, 208, 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with HBV DNA 10(5) copies/mL or a 2 log10 reduction from Baseline HBV DNA level</measure>
    <time_frame>Week 52, 104, 156, 208, 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with HBeAg loss</measure>
    <time_frame>Week 52, 104, 156, 208, 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with HBeAg seroconversion</measure>
    <time_frame>Week 52, 104, 156, 208, 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects developing N236T and A181V HBV DNA genotypic mutations associated with ADV resistance</measure>
    <time_frame>Week 52, 104, 156, 208, 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with HBV DNA undetectable (&lt;300 copies/mL)</measure>
    <time_frame>Week 52, 104, 156, 208, 260</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">480</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Adefovir Dipivoxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADV 10mg tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adefovir Dipivoxil matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Adefovir Dipivoxil matched placebo one tablet once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AAAA</intervention_name>
    <description>Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)</description>
    <arm_group_label>Adefovir Dipivoxil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AAPA</intervention_name>
    <description>Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)</description>
    <arm_group_label>Adefovir Dipivoxil</arm_group_label>
    <arm_group_label>Adefovir Dipivoxil matched placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAAA</intervention_name>
    <description>Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)</description>
    <arm_group_label>Adefovir Dipivoxil</arm_group_label>
    <arm_group_label>Adefovir Dipivoxil matched placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-65 years

          -  Presence of HBsAg and HBeAg at the time of screening and for at least 6 months prior
             to screening.

          -  Positive HBV DNA plasma assay with screening value equal or more than 10 (6) copies/mL
             (Roche COBAS AMPLICORTM HBV MONITOR Test, LLOD less than 300 copies/mL) at the time of
             screening (within 4 weeks of randomisation).

          -  Evidence of elevated serum ALT levels defined as serum ALT level greater than or equal
             to 2.0 times (inclusive) the upper limit of the normal range (ULN) in the previous 6
             months, and serum ALT levels greater than 1.0 times the ULN at the time of screening.

        Exclusion Criteria:

          -  Evidence of hepatocellular carcinoma;

          -  Clinical signs of liver decompensation;

          -  Serum creatinine more than 1.5 mg/dL;

          -  ALT more than 10 x ULN; seropositivity for hepatitis C or D virus or HIV;

          -  Lamivudine therapy within 3 months prior to screening;

          -  ADV therapy or any other anti-HBV therapy within the previous 6 months;

          -  Use of systemic antiviral agents, immunomodulators, immunosuppressive therapy, Chinese
             Traditional Medicines or agents known to lower ALT levels during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chongquin</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <last_update_submitted>April 2, 2009</last_update_submitted>
  <last_update_submitted_qc>April 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>HBV DNA suppression</keyword>
  <keyword>ALT normalisation</keyword>
  <keyword>Viral resistance</keyword>
  <keyword>HBeAg seroconversion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 4, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>December 8, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

